Drug Involvement of Fatally Injured Drivers

NHTSA · 2010 · ROSA P / United States. Department of Transportation. National Highway Traffic Safety Administration

archive: archived pipeline: cataloged verified

Get this paper ↗ (full text — opens at the source; we link to it, we don't host it)

Summary

This report, published by the National Highway Traffic Safety Administration (NHTSA) in 2010, addresses the statistical landscape of drug involvement among drivers involved in fatal motor vehicle crashes in the United States. While data regarding alcohol-impaired driving is widely available, information concerning other drugs has historically been less discussed. The study utilizes data from the Fatality Analysis Reporting System (FARS), a census of fatal crashes, to quantify drug testing rates and positive results for fatally injured drivers between 2005 and 2009. The report aims to provide a clear statistical summary while highlighting significant limitations in data collection and interpretation. The methodology relies on FARS variables that track drug testing status, test type, and results. Drivers are categorized by the presence of narcotics, depressants, stimulants, hallucinogens, cannabinoids, phencyclidines (PCP), anabolic steroids, or inhalants. The analysis focuses exclusively on fatally injured drivers, as their testing rates are higher than those of surviving drivers. The report explicitly notes that "drug involvement" indicates only the presence of substances in the driver’s system, not necessarily impairment or causation of the crash. Furthermore, the data excludes nicotine, aspirin, alcohol, and post-crash administered drugs, and lacks measures of drug concentration. Key findings indicate that both the proportion of fatally injured drivers tested for drugs and the proportion testing positive increased over the five-year period. In 2009, 63% of fatally injured drivers were tested, representing 13,801 individuals out of 21,798 total fatalities. Of these, 3,952 drivers (18% of all fatally injured drivers) tested positive for drugs. Among drivers with known test results, 33% tested positive in 2009, up from 28% in 2005. Significant geographic disparities exist; for instance, in 2009, Maine reported no tests, while Mississippi reported only 2% tested, whereas several states reported testing rates exceeding 80%. Additionally, 8% of nationally tested drivers had unknown results in 2009. The significance of this report lies in its cautionary approach to interpreting drug involvement statistics. The authors emphasize that drug presence does not equate to impairment. Major limitations include inconsistent state laws, varying testing policies, different concentration thresholds for positive results, and disparities in police accident reporting. These factors introduce potential biases, with some states possibly under-reporting and others over-reporting drug involvement. Consequently, national and state counts of drug-involved crashes must be interpreted with care, acknowledging that the drug involvement rates among untested drivers or those with unknown results may differ systematically from those with available data.

Key finding

In 2009, 3,952 fatally injured U.S. drivers tested positive for drugs, representing 18% of all fatally injured drivers and 33% of those with known drug test results.

Methodology

dataset

Provenance

The full processing record for this entry. Every stage of this paper's journey through the pipeline is logged — what ran, with which tool and model, how many attempts it took, and when it last completed. Discovered via bulk_ingest_rosap on 2026-05-23 (7 acquisition events logged).

Summary generated by qwen3.6-27b-prismaquant on 2026-06-10; verification: verified.

Topics

Ranked by relevance to this paper. Hover a topic for its definition.

• illicit drugs

Information type

What kind of knowledge this paper contributes, grouped by family — independent of topic (what it is about) and method (how it was studied).

• Empirical Findings: crash risk outcomes, observational prevalence